Skip to main content
Premium Trial:

Request an Annual Quote

Abbott Gets FDA Emergency Use Authorization for Monkeypox PCR Test

NEW YORK — The US Food and Drug Administration said Friday it has granted Emergency Use Authorization for Abbott's real-time PCR monkeypox test, the Alinity m MPXV assay.

The test is for use by CLIA-certified laboratories for the detection of monkeypox virus DNA from lesion swab samples. In its authorization letter, the FDA noted that monkeypox virus DNA is generally detectable in human pustular or vesicular lesion specimens during the acute phase of infection.

The assay can be used on Abbott's Alinity m instrument or other authorized instruments, which perform sample preparation, PCR assembly, amplification, detection, and result calculation and reporting, the FDA said, adding it requires use of the Alinity m MPXV CTRL Kit.

The US Department of Health and Human Services declared a state of emergency on Aug. 9 in response to outbreaks with the virus within the United States. Quest Diagnostics received the first EUA for its Monkeypox Virus Qualitative Real-Time PCR test, which detects monkeypox and other non-variola orthopoxvirus DNA in lesion swab specimens.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.